| Harlan K Shinkle, DDS | |
|
610 E 2nd St, Pratt, KS 67124-2912 | |
| (620) 672-5536 | |
| (620) 672-3624 |
| Full Name | Harlan K Shinkle |
|---|---|
| Gender | Male |
| Speciality | Dentist - General Practice |
| Location | 610 E 2nd St, Pratt, Kansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881687887 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 5793 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Harlan K Shinkle, DDS 1113 Champa St, Pratt, KS 67124-1205 Ph: (620) 672-2078 | Harlan K Shinkle, DDS 610 E 2nd St, Pratt, KS 67124-2912 Ph: (620) 672-5536 |
News Archive
Researchers at the Icahn School of Medicine at Mount Sinai reported that a virulent new strain of influenza - the virus that causes the flu - appears to retain its ability to cause serious disease in humans even after it develops resistance to antiviral medications. The finding was included in a study that was published today in the journal Nature Communications.
Young people aged under 18 years are more likely than adults to catch swine flu from an infected person in their household, according to a new study published today in the New England Journal of Medicine.
Neogenix Oncology announced today that the U.S. Patent and Trade Mark Office has issued a Notice of Allowance for a patent application related to its 16C3 antibody. Discovered and developed by Neogenix Oncology, this antibody appears to have anti-tumor activity for both pancreatic and colorectal tumors, and may have both therapeutic and diagnostic utility. The antibody may have activity in other tumors as well, which the company will explore at such time as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody.
Researchers from the US tested the prophylactic potential of a combination of 2 mAbs administered 3 or 75 days before respiratory challenge in rhesus macaques. They used the rhesus macaque model to test the added benefit of combinatory parenteral administration of 2 high-affinity anti-SARS-CoV-2 mAbs - C144-LS and C135-LS. These mAbs were developed to neutralize the virus and tweaked to improve their pharmacokinetics.
Researchers from Children's Hospital Boston and Brigham and Women's Hospital have identified an important genetic cause of a devastating kidney disease that is the second leading cause of kidney failure in children, according to The NephCure Foundation.
› Verified 3 days ago
John D Mathes, DDS Dentist Medicare: Medicare Enrolled Practice Location: 603 N Main, Pratt, KS 67124 Phone: 620-672-9922 | |
Steven M Kunz, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 501 S. Fincham, Pratt, KS 67124 Phone: 620-672-3612 Fax: 620-672-3314 | |
Dr. Lee Ronald Ingram, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 105 W 4th St, Pratt, KS 67124 Phone: 620-672-3612 Fax: 620-672-3314 | |
Kole Robert Lopez, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 603 S Main St, Pratt, KS 67124 Phone: 620-672-9922 Fax: 620-672-9966 | |
Dr. Dave J Johnston, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 219 S Ninnescah, Pratt, KS 67124 Phone: 620-672-6111 Fax: 626-067-2611 | |
Carson Terry Hopkins, DMD Dentist Medicare: Medicare Enrolled Practice Location: 105 W 4th St, Pratt, KS 67124 Phone: 620-672-3612 Fax: 620-672-3314 |